You are here

  • Home
  • Archive
  • Volume 21, Issue 6
  • Expression of ERCC1, p53, and Class III β-Tubulin Do Not Reveal Chemoresistance in Endometrial Cancer: Results From an Immunohistochemical Study

Article info

Article menu
Download PDFPDF
Uterine Cancer
Expression of ERCC1, p53, and Class III β-Tubulin Do Not Reveal Chemoresistance in Endometrial Cancer: Results From an Immunohistochemical Study

Authors

  1. Address correspondence and reprint requests to Frédéric Amant, MD, PhD, Division of Gynecological Oncology, Department of Obstetrics and Gynecology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium. E-mail: frederic.amant{at}uz.kuleuven.ac.be.

Citation

Vandenput I, Capoen A, Coenegrachts L, et al
Expression of ERCC1, p53, and Class III β-Tubulin Do Not Reveal Chemoresistance in Endometrial Cancer: Results From an Immunohistochemical Study
International Journal of Gynecologic Cancer 2011;21:1071-1077.

Publication history

  • Received February 2, 2011
  • First published August 1, 2011.
Online issue publication 
February 26, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Copyright © 2011 by IGCS and ESGO